Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Ovid Therapeutics (OVID) Enterprise Value (2017 - 2026)

Ovid Therapeutics filings provide 11 years of Enterprise Value readings, the most recent being -$155.5 million for Q1 2026.

  • Quarterly Enterprise Value fell 261.71% to -$155.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$155.5 million through Mar 2026, down 261.71% year-over-year, with the annual reading at -$69.1 million for FY2025, 30.23% down from the prior year.
  • Enterprise Value hit -$155.5 million in Q1 2026 for Ovid Therapeutics, down from -$69.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$25.5 million in Q3 2025 and bottomed at -$166.7 million in Q1 2022.
  • Average Enterprise Value over 5 years is -$93.7 million, with a median of -$88.9 million recorded in 2024.
  • The largest annual shift saw Enterprise Value skyrocketed 59.61% in 2025 before it tumbled 261.71% in 2026.
  • Ovid Therapeutics' Enterprise Value stood at -$126.1 million in 2022, then grew by 16.1% to -$105.8 million in 2023, then soared by 49.85% to -$53.1 million in 2024, then crashed by 30.23% to -$69.1 million in 2025, then tumbled by 125.01% to -$155.5 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Enterprise Value are -$155.5 million (Q1 2026), -$69.1 million (Q4 2025), and -$25.5 million (Q3 2025).